12th PAGE Meeting

Verona - Italy
12 - 13 June, 2003

View abstracts

Home / 2003 – Verona – Italy / Abstracts

← Back to filters

Abstracts (23)

Willem DeWinter(1), Joost DeJongh(1), Bart Ploeger(1), Richard Urquhart(2), Ian Moules(2), David Eckland(2), and Meindert Danhof(1)

Disease progression modelling; application of population analysis to distinguish between symptomatic and protective treatment effects.

C. Hu, J.Y. Kim, K.H.P. Moore, M.E. Sale

A Modeling Approach to Assessing Bioequivalence (BE) with Presence of Sparsely Sampled Subjects

B. Vrijens(1-2), S.L. Mayer(1),R.Rode(3), R. Bertz(3), J. Urquhart(1)

Dose-Timing Information Improves The Clinical Explanatory Power Of Data On Patient Adherence To Antiretroviral Drug Regimens

James B. Bassingthwaighte

Developing Integrated Cell Systems

Estelle Kuhn and Marc Lavielle

Maximum likelihood estimation in nonlinear mixed effects models

Mark Sale

Applications of Distributed computing in Drug development

Roy Anderson

Patient adherence and the evolution of resistance to anti-viral agents

Joachim Stangier, Karl-Heinz Liesenfeld, Christiane Tillmann, Inaki Troconiz (#), Hans Guenter Schaefer

Population pharmacokinetics/-dynamics of dabigatran, the active form of the new oral direct thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing hip replacement

William R. Gillespie

Case Study in the Use of Bayesian Hierarchical Modeling and Simulation for Design and Analysis of a Clinical Trial

K. Kowalski (1), M. Hutmacher (2)

Evaluation of a Random Sparse Sampling Design: An Assessment of Power and Bias Using Simulation

Gianluca Nucci and Roberto Gomeni

Design and power PK/PD experiments using very sparse data

Emmanuelle Comets(1, 3), Kazumasa Ikeda(2), Yusuke Tanigawara(3)

Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients

Miller R, Kowalski KG, Liu J, Frame B, Burger PJ, Corrigan BW, Bockbrader HN, Lalonde R.

Pregabalin Exposure-Adverse Event Analysis in Patients With Neuropathic Pain, Generalized Anxiety Disorder, or Partial Seizures

Katarina Jelic, Morten Colding-Jørgensen

Obesity and Insulin Resistance: A Fat Link

Christoffer W. Tornøe(1), Henrik Agersø(1), Henrik A. Nielsen(2), Henrik Madsen(2), and E. Niclas Jonsson(3)

Population Pharmacokinetic Modelling of a Subcutaneous Depot for GnRH Antagonist Degarelix

N. Hayashi(1), K. P. Zuideveld(1), P. Jordan(2), R. Gieschke(1)

A Mechanism-Based PK/PD Model Predicts the Time-Course of Hematological responses for Epoetin beta

Brunhild Schiltmeyer1, Joachim Boos1, Matthias Schwab2, Thomas Mürdter2, Thomas Klingebiel3, G. Fleischhack5, Josef Vormoor1, Bernd Gruhn4 and Georg Hempel1

Population Pharmacokinetics of Intravenous Busulfan in Children

T. Kerbusch (1,2), U. Wählby (2), A. Skerjanec (3), P.A. Milligan (1), M.O. Karlsson(2)

Assessment of the in vivo relative potency of the hydroxylated metabolite of darifenacin for the reduction of salivary flow using a population pharmacokinetic-pharmacodynamic meta-analysis

MR, Ballester, MJ Barbanoj, R Antonijoan, M Yritia, M Valle.

Absorption and plasma kinetics of multiple high oral doses of glucose: influence of glibenclamide.

Lars Lindbom

Parallel computing under Linux

Fredrik Jonsson and Niclas Jonsson

A pharmacodynamic model for Scandinavian Stroke Scale data

M. C. Rosario (1), P. Jacqmin (2), Pat Dorr(1), Manos Perro (1) & Elna van der Ryst (1)

A PK-PD-disease model to support the design of clinical trials of drugs for the treatment of HIV

Duffull SB (1), Isbister GK (2), Dawson AH (2), Hackett LP (3), Whyte IM (2).

Estimating population pharmacokinetic parameters when dose and dose-time are not known accurately